ProMIS Neurosciences (PMN) Change in Cash (2021 - 2026)
ProMIS Neurosciences' (PMN) quarterly Change in Cash came in at $57.7 million in Q1 2026, up 1271.09% YoY from $4.2 million in Q1 2025, and up 721.57% on a QoQ basis from -$9.3 million in Q4 2025.
ProMIS Neurosciences (PMN) Change in Cash (2021 - 2026) Analysis & Trends
ProMIS Neurosciences (PMN) has 6 years of Change in Cash data on file, last reported at $57.7 million in Q1 2026.
- Quarterly Change in Cash rose 1271.09% year-over-year to $57.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $55.5 million (up 845.06% YoY) and the FY2025 annual result came in at -$7.2 million, down 1135.27% from the prior year.
- Change in Cash improved to $57.7 million in Q1 2026, from -$9.3 million in the prior quarter.
- In the past five years, Change in Cash ranged from a high of $57.7 million in Q1 2026 to a low of -$10.1 million in Q1 2024.
- A 5-year average of $2.8 million and a median of -$3.2 million in 2022 frame the typical range for Change in Cash.
- Annual changes were most pronounced in 2023 — Change in Cash sank 318.42% — and 2026, when it surged 1271.09%.
- Tracing PMN's Change in Cash over 5 years: stood at $2.0 million in 2022, then tumbled by 318.42% to -$4.3 million in 2023, then sank by 93.1% to -$8.2 million in 2024, then decreased by 12.57% to -$9.3 million in 2025, then soared by 721.57% to $57.7 million in 2026.
- The last three Change in Cash figures came in at $57.7 million (Q1 2026), -$9.3 million (Q4 2025), and $10.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 649.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.60 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -185.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 427.25 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -2.94 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.42 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | ProMIS Neurosciences | 132.34 Mn | 78.87 Mn | - | -10.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -10.39 Mn |
| Mar 31, 2026 | 57.70 Mn |
| Dec 31, 2025 | -9.28 Mn |
| Sep 30, 2025 | 10.89 Mn |
| Jun 30, 2025 | -3.85 Mn |
| Mar 31, 2025 | -4.93 Mn |
| Dec 31, 2024 | -8.25 Mn |
| Sep 30, 2024 | 20.54 Mn |
| Jun 30, 2024 | -1.50 Mn |
| Mar 31, 2024 | -10.10 Mn |
| Dec 31, 2023 | -4.27 Mn |
| Sep 30, 2023 | 15.65 Mn |
| Jun 30, 2023 | -2.11 Mn |
| Mar 31, 2023 | -2.54 Mn |
| Dec 31, 2022 | 1.96 Mn |
| Sep 30, 2022 | -4.98 Mn |
| Jun 30, 2022 | -4.85 Mn |
| Mar 31, 2022 | -3.19 Mn |
| Dec 31, 2021 | -3.95 Mn |
| Sep 30, 2021 | 15.32 Mn |